Welcome to our dedicated page for Hims & Hers Health SEC filings (Ticker: HIMS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Hims & Hers Health, Inc. (NYSE: HIMS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, giving investors a detailed view of how this health and wellness platform operates and evolves. Through its filings with the U.S. Securities and Exchange Commission, Hims & Hers reports on financial performance, material events, governance changes, and key agreements that shape its digital health business.
Core documents such as annual reports on Form 10‑K and quarterly reports on Form 10‑Q (when available) explain the company’s subscription-based online revenue model, wholesale revenue from non-prescription product sales, and metrics like subscribers and monthly online revenue per average subscriber. These filings also discuss risks, accounting policies, and segment information that help readers understand the structure of the Hims & Hers platform and its growth drivers.
Current reports on Form 8‑K are particularly important for tracking significant developments. Recent 8‑Ks describe the authorization of a $250 million share repurchase program, the completion and use of a prior $100 million repurchase program, leadership changes such as the transition of the Chief Operating Officer role, and the entry into a long-term lease for a large facility in New Albany, Ohio, to support office, research and development, laboratory, manufacturing, and pharmaceutical dispensing activities. Other 8‑Ks furnish earnings press releases and shareholder letters, which outline quarterly financial results and management’s commentary.
Investors can also use SEC filings to follow strategic moves like the definitive agreement to acquire YourBio Health, which brings patented, virtually painless TAP and HALO blood sampling technologies into the Hims & Hers ecosystem, and to see how the company communicates material information through its designated disclosure channels. On Stock Titan, AI-powered tools can help summarize lengthy filings, highlight key sections related to revenue, capital allocation, share repurchases, and major contracts, and surface insider and governance-related information reported in applicable forms. This makes it easier to interpret complex regulatory documents and to connect them with the company’s broader strategy in digital health and wellness.
Form 144/A from Hims & Hers Health, Inc. (HIMS) reports a proposed sale of 154,958 common shares through Goldman Sachs & Co. LLC on 09/22/2025, with an aggregate market value of $9,161,116.96. The filing shows 217,641,958 shares outstanding. The securities to be sold were acquired mainly as compensation: multiple Restricted Stock Unit grants on 09/15/2025, 09/15/2024, 06/15/2024 and cashless exercises of stock options on 02/24/2022 and 03/01/2023. The filing also discloses sales by Oluyemi Okupe during the past three months totaling several transactions, including a 145,000-share sale on 09/15/2025 for $8,026,083.50. The notice includes the seller's representation that no undisclosed material adverse information is known.
Hims & Hers Health, Inc. Form 144 notice shows a proposed sale of 250 Class A shares through Fidelity Brokerage Services (NYSE) on 10/01/2025, with an aggregate market value of $14,000. The shares are reported as acquired on 10/01/2025 via options granted 03/01/2023 and will be paid in cash.
The filing also lists seven prior Class A sales by Michael Y. Chi during July–September 2025 totaling $3,717,768.50 in gross proceeds. The filer affirms no undisclosed material adverse information and provides broker and sale dates but omits filer CIK and full contact details in the provided text.
Oluyemi Okupe, Chief Financial Officer of Hims & Hers Health, Inc. (HIMS), executed option exercises and share sales under a Rule 10b5-1 plan on 09/29/2025. He exercised 49,832 stock options with a $5.01 exercise price and sold 85,000 Class A common shares at a weighted average price of $60.1991 (sales ranged $59.95–$60.48). Following the reported transactions, the filing shows 70,232 shares directly beneficially owned and 7,853 shares indirectly held by the Oluyemi Okupe Separate Property Trust dated 9-1-2021. The filing discloses remaining derivative holdings totaling 189,952 option shares following the transactions and notes vesting terms and the 10b5-1 plan adoption date of May 21, 2025.
Soleil Boughton, Chief Legal Officer of Hims & Hers Health, Inc. (HIMS), reported an open-market sale of Class A common stock. On 09/29/2025 she disposed of 2,637 shares at $58.79 per share pursuant to a Rule 10b5-1 trading plan adopted August 28, 2024. After the sale she beneficially owned 163,767 shares, held directly. The Form 4 was filed by one reporting person and signed on behalf of the reporting person by an attorney-in-fact on 09/30/2025. The filing discloses no derivative transactions and provides no financial performance or forward-looking statements.
Hims & Hers Health, Inc. (HIMS) Form 144 notice reports a proposed sale of 2,637 Class A shares to be executed through Fidelity Brokerage Services on 09/29/2025 with an aggregate market value of $155,029.23, against 217,641,958 shares outstanding. The filing states those shares were acquired on 09/15/2025 by restricted stock vesting and were paid as compensation.
The filer discloses multiple recent Class A sales by Soleil Boughton during June–September 2025, each around 2,571–2,637 shares, generating gross proceeds reported per trade. The notice includes the standard Rule 144 representation regarding material nonpublic information and is a routine compliance filing for insider sales of vested compensation shares.
Michael Chi, Chief Commercial Officer of Hims & Hers Health, Inc. (HIMS), reported multiple transactions on Form 4. On 03/07/2025 he disposed of 5,700 Class A shares as a gift to a donor-advised fund, leaving 291,439 shares beneficially owned. On 09/24/2025 he exercised 2,100 stock options with an exercise price of $5.01 under a Rule 10b5-1 trading plan adopted 03/04/2025, and concurrently sold 2,100 shares at $56.52. The Form 4 shows 2,100 underlying shares from the options and indicates total Class A beneficial ownership figures of 174,042 shares for options and 291,439–293,539 shares across reported lines. The filing discloses that the options vest over a four-year service schedule that began in 03/2022.
Hims & Hers Health, Inc. (HIMS) Chief Financial Officer Oluyemi Okupe sold 23,584 shares of Class A common stock on 09/22/2025 at an average weighted price of $57.7411 per share under a Rule 10b5-1 trading plan adopted May 21, 2025. Following the sale, the reporting person directly beneficially owns 105,400 shares and indirectly owns 7,853 shares held by the Oluyemi Okupe Separate Property Trust dated 9-1-2021. The filer certifies the sales were effected under the pre-established plan and offers to provide the exact breakdown of shares sold at each price within the reported $57.38–$58.245 range if requested by regulators or the issuer.
Form 144 notice by a holder of HIMS Class A common stock proposes sale of 2,100 shares on 09/24/2025 through Fidelity Brokerage Services (NYSE). The filer indicates the 2,100 shares were acquired the same day as an option exercise tied to an option granted on 02/24/2022 and the consideration is listed as compensation. The filing lists prior sales by the same person, Michael Y. Chi, totaling 60,349 shares sold in the past three months for aggregate gross proceeds of $3,599,076.50. The issuer name, SEC file number and the filer CIK/CCC are not provided in the document text. The filing includes the required representation that the seller is not aware of undisclosed material adverse information.
Insider sale notice for HIMS (Form 144) — The filer plans to sell 154,958 common shares through Goldman Sachs & Co. LLC on the NYSE with an aggregate market value of $8,941,076.60, against 217,641,958 shares outstanding. The notice lists the securities were largely acquired as compensation: several restricted stock unit grants dated 09/15/2025 (11,747; 4,110; 5,153; 2,574) and earlier stock option-related acquisitions on 02/24/2022 and 03/01/2023. The filing also discloses multiple sales by Oluyemi Okupe in the prior three months, including a 145,000-share sale on 09/15/2025 generating about $8.03 million. The notice affirms the signer is not aware of undisclosed material adverse information.
Insider sale notice for HIMS (Form 144) — The filer plans to sell 154,958 common shares through Goldman Sachs & Co. LLC on the NYSE with an aggregate market value of $8,941,076.60, against 217,641,958 shares outstanding. The notice lists the securities were largely acquired as compensation: several restricted stock unit grants dated 09/15/2025 (11,747; 4,110; 5,153; 2,574) and earlier stock option-related acquisitions on 02/24/2022 and 03/01/2023. The filing also discloses multiple sales by Oluyemi Okupe in the prior three months, including a 145,000-share sale on 09/15/2025 generating about $8.03 million. The notice affirms the signer is not aware of undisclosed material adverse information.
Hims & Hers Health, Inc. filed a current report to remind investors how it shares important company information with the public. The company explains that news about its business, products, services and corporate updates may be shared across multiple channels, not just through SEC filings or traditional press releases.
Hims & Hers points investors to several key sources: its main consumer websites at hims.com and forhers.com, its investor relations site at investors.hims.com, and its news site at news.hims.com. The company also highlights social media, including its and CEO Andrew Dudum’s accounts on X and LinkedIn, as places where information that could be considered important may appear. The company notes that this list of channels may change over time.
Hims & Hers Health, Inc. filed a current report to remind investors how it shares important company information with the public. The company explains that news about its business, products, services and corporate updates may be shared across multiple channels, not just through SEC filings or traditional press releases.
Hims & Hers points investors to several key sources: its main consumer websites at hims.com and forhers.com, its investor relations site at investors.hims.com, and its news site at news.hims.com. The company also highlights social media, including its and CEO Andrew Dudum’s accounts on X and LinkedIn, as places where information that could be considered important may appear. The company notes that this list of channels may change over time.